NEW YORK (GenomeWeb) – Caris Life Sciences today announced a collaboration with COTA to measure the health and economic impact of the Caris Molecular Intelligence panomic tumor profiling service for cancer patients.
Under the terms of the deal, the firms will track and combine de-identified molecular data and clinical outcomes in a longitudinal database that will be expanded across the Caris Centers of Excellence for Precision Medicine (COE) Network.
The COE Network comprises cancer centers that have demonstrated a commitment to precision medicine and will collaborate to use advanced data to establish standards of care for molecular tumor profiling. The network will use the data collected through the Caris-COTA partnership to reinforce guidelines with research publications and to develop a better understanding of cancer and the most effective treatments, Caris said.
The collaboration combines Caris' database of molecular information with COTA's classification and real-time, longitudinal patient tracking capabilities to expand access to and the use of Caris' tumor profile service, Caris Chairman and CEO David Halbert said in a statement. He added that the deal will lead to new insights into cancer treatment outcomes, the cost of care, as well as accelerate the discovery and delivery of more personalized targeted therapies.
COTA CEO Eric Schultz added that "the combination of genomic and proteomic molecular data with COTA's precise classification and clinical outcomes information and economic data will provide meaningful insights for both physicians and payers, especially as the industry moves toward value-based treatment and reimbursement practices."
Financial and other terms of the agreement were not disclosed.